H Jiang1, Q Li1, S Yu1, Y Yu1, Y Wang1, W Li1, Y Cui1, T Liu2. 1. Department of Medical Oncology, Zhongshan Hospital, Fudan University, Building 8, 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. 2. Department of Medical Oncology, Zhongshan Hospital, Fudan University, Building 8, 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. liutianshu1969@126.com.
Abstract
PURPOSE: We aim to investigate the correlation of HER2 expression with liver metastasis and the impact of HER2 status and trastuzumab therapy on the prognosis of gastric cancer with liver metastasis (GCLM) patients. METHODS: This prospective observational study was carried out in Shanghai Zhongshan Hospital, Fudan University, from January 2012 to June 2015. HER2 status and baseline characteristics were collected from the patient record. GCLM patients were divided into three groups according to HER2 status and trastuzumab therapy. RESULTS: A total of 290 patients were included, and94 patients were diagnosed with liver metastasis. The HER2 positivity was 37.2 % (35/94) in GCLM patients and 21 % (61/290) in the overall GC patients. Among 94 GCLM patients, 28 HER2-positive patients received trastuzumab-based therapy (group A), 7 HER2-positive patients received chemotherapy alone (group B) and the other 59 patients were HER2 negative (group C). The median progression-free survival (PFS) for groups A, B and C was 7.83, 6.30 and 5.33 months, respectively (P = 0.007). The median overall survival (OS) for groups A, B and C was 12.00, 10.47 and 8.67 months, respectively (P = 0.056). Further Cox analysis showed that there was no significant difference in OS (P = 0.917) and PFS (P = 0.456) between group B and C. CONCLUSIONS: HER2 positivity was higher in GCLM patients. HER2 status itself was not an independent prognostic factor in GCLM patients. Trastuzumab-based therapy could significantly improve survival in HER2-positive GCLM patients.
PURPOSE: We aim to investigate the correlation of HER2 expression with liver metastasis and the impact of HER2 status and trastuzumab therapy on the prognosis of gastric cancer with liver metastasis (GCLM) patients. METHODS: This prospective observational study was carried out in Shanghai Zhongshan Hospital, Fudan University, from January 2012 to June 2015. HER2 status and baseline characteristics were collected from the patient record. GCLM patients were divided into three groups according to HER2 status and trastuzumab therapy. RESULTS: A total of 290 patients were included, and94 patients were diagnosed with liver metastasis. The HER2 positivity was 37.2 % (35/94) in GCLM patients and 21 % (61/290) in the overall GC patients. Among 94 GCLM patients, 28 HER2-positive patients received trastuzumab-based therapy (group A), 7 HER2-positive patients received chemotherapy alone (group B) and the other 59 patients were HER2 negative (group C). The median progression-free survival (PFS) for groups A, B and C was 7.83, 6.30 and 5.33 months, respectively (P = 0.007). The median overall survival (OS) for groups A, B and C was 12.00, 10.47 and 8.67 months, respectively (P = 0.056). Further Cox analysis showed that there was no significant difference in OS (P = 0.917) and PFS (P = 0.456) between group B and C. CONCLUSIONS:HER2 positivity was higher in GCLM patients. HER2 status itself was not an independent prognostic factor in GCLM patients. Trastuzumab-based therapy could significantly improve survival in HER2-positive GCLM patients.
Authors: Maria D Begnami; Emy Fukuda; José H T G Fregnani; Suely Nonogaki; André L Montagnini; Wilson L da Costa; Fernando A Soares Journal: J Clin Oncol Date: 2011-06-27 Impact factor: 44.544
Authors: K Sakai; S Mori; T Kawamoto; S Taniguchi; O Kobori; Y Morioka; T Kuroki; K Kano Journal: J Natl Cancer Inst Date: 1986-11 Impact factor: 13.506
Authors: Carlos Gómez-Martin; Elena Garralda; M José Echarri; Anabel Ballesteros; Alberto Arcediano; José Luis Rodríguez-Peralto; Manuel Hidalgo; Fernando López-Ríos Journal: J Clin Pathol Date: 2012-05-08 Impact factor: 3.411
Authors: Q Li; H Li; H Jiang; Y Feng; Y Cui; Y Wang; Y Ji; Y Yu; W Li; C Xu; S Yu; R Zhuang; T Liu Journal: Clin Transl Oncol Date: 2017-11-22 Impact factor: 3.405
Authors: Sebastian Schade; Ute Koenig; Ardian Mekolli; Jochen Gaedcke; Albrecht Neesse; Johanna Reinecke; Marius Brunner; Ali Seif Amir Hosseini; Julia Kitz; Philipp Stroebel; Joachim Lotz; Michael Ghadimi; Volker Ellenrieder; Alexander Koenig Journal: Case Rep Gastroenterol Date: 2022-02-17